Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Daiichi Sankyo
Dow
Harvard Business School
US Department of Justice
UBS
McKinsey
Boehringer Ingelheim
Teva

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,071,577

« Back to Dashboard

Which drugs does patent 8,071,577 protect, and when does it expire?

Patent 8,071,577 protects NATAZIA and is included in one NDA.

This patent has thirty-eight patent family members in thirty-five countries.
Summary for Patent: 8,071,577
Title:Multi-phase contraceptive preparation based on a natural estrogen
Abstract: The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenone. The multiphase preparation is characterized by a first phase consisting of 2 daily dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenone and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenone, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.
Inventor(s): Endrikat; Jan (Kirkland, CA), Duesterberg; Bernd (Oberkraemer, DE)
Assignee: Bayer Pharma Aktiengesellschaft (Berlin, DE)
Application Number:11/578,771
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,071,577
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,071,577

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare NATAZIA dienogest; estradiol valerate TABLET;ORAL 022252-001 May 6, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y PREVENTION OF PREGNANCY ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,071,577

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2004 019 743Apr 20, 2004
PCT Information
PCT FiledApril 15, 2005PCT Application Number:PCT/EP2005/004022
PCT Publication Date:November 03, 2005PCT Publication Number: WO2005/102247

International Family Members for US Patent 8,071,577

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 048830 ➤ Try a Free Trial
Argentina 084229 ➤ Try a Free Trial
Austria 473734 ➤ Try a Free Trial
Australia 2005235418 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Citi
Queensland Health
Teva
Colorcon
Moodys
US Army
Deloitte
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.